News | September 14, 2024
Briefs: RPG Life Sciences and Lasa Supergenerics
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
ALS patients experience neuroinflammation and rapid neurodegeneration
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
The EIR was issued post the last inspection of the facility conducted from May 6-10, 2024 which concluded with zero FDA 483 observations
Subscribe To Our Newsletter & Stay Updated
